Skip to content
Find a Provider
Healthcare provider image placeholder

Philip Anthony Sutera, M.D.

he/him/his

Radiation Oncology

No ratings currently available, see text in Ratings section below for explanation.

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Call Center (585) 276-3000

Locations

Wilmot Cancer Institute - Webster

875 Hard Road
Webster, NY 14580

(585) 602-3150 Get Directions

About Me

Faculty Appointments

Assistant Professor - Department of Radiation Oncology (SMD)

Credentials

Residency & Fellowship

Residency, Radiation Oncology, Johns Hopkins University School of Medicine. 2020 - 2024

Internship, Internal Medicine, Allegheny General Hospital. 2019 - 2020

Education

MD | University of Pittsburgh School of Medicine. 2019

Awards

ASTRO Annual Meeting Abstract Award. 2024

ASCO Conquer Cancer Merit Award. 2024

American Radium Society Travel Grant. 2023

Bert and Sally O'Malley Award for Outstanding work in Medical Student Research. 2019

RSS Best Medical Resident Challenge-Abstract. 2019

Best of ASTRO Meeting Abstract. 2018

Deans Research Fellowship Funding. 2017

Chemistry Department Award. 2014

Junior Scholar Award: Department of Chemistry. 2013

Research Experience for Undergrads Grant. 2012

Honorary Science Scholarship. 2009 - 2014

Publications

Journal Articles

Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic Castration-Sensitive prostate cancer.

Wang JH, Deek MP, Mendes AA, Song Y, Shetty A, Bazyar S, Van der Eecken K, Chen E, Showalter TN, Royce TJ, Todorovic T, Huang HC, Houck SA, Yamashita R, Kiess AP, Song DY, Lotan T, DeWeese T, Marchionni L, Ren L, Sawant A, Simone N, Berlin A, Onal C, Esteva A, Feng FY, Tran PT, Sutera P, Ost P

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.. 2024 November 6202 :110618. Epub 11/06/2024.

PIK3/Akt/mTOR pathway alterations in metastatic castration-sensitive prostate cancer.

Sutera P, Kim J, Kumar R, Deek RA, Stephenson R, Mayer T, Saraiya B, Ghodoussipour S, Jang T, Golombos D, Packiam V, Ennis R, Hathout L, Jabbour SK, Guler O, Onal C, Tran PT, Deek MP

The Prostate.. 2024 October 84 (14):1301-1308. Epub 07/17/2024.

Impact of definitive radiotherapy on metabolic response measured with Ga-PSMA-PET/CT in patients with intermediate-risk prostate cancer.

Onal C, Guler OC, Torun N, Elmali A, Sutera P, Deek MP, Reyhan M, Yavuz M, Tran PT

The Prostate.. 2024 August 6 Epub 08/06/2024.

Evaluation of Treatment Outcomes of Prostate Cancer Patients With Lymph Node Metastasis Treated With Definitive Radiotherapy: Comparative Analysis of PSMA PET/CT and Conventional Imaging.

Onal C, Guler OC, Erpolat P, Hurmuz P, Sutera P, Deek MP, Elmali A, Yilmaz MT, Koken UH, Yavuz M, Ozyigit G, Tran PT

Clinical nuclear medicine.. 2024 August 149 (8):e383-e389. Epub 05/31/2024.

Machine learning predicts conventional imaging metastasis-free survival (MFS) for oligometastatic castration-sensitive prostate cancer (omCSPC) using prostate-specific membrane antigen (PSMA) PET radiomics.

Cao Y, Sutera P, Silva Mendes W, Yousefi B, Hrinivich T, Deek M, Phillips R, Song D, Kiess A, Cem Guler O, Torun N, Reyhan M, Sawant A, Marchionni L, Simone NL, Tran P, Onal C, Ren L

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.. 2024 July 31199 :110443. Epub 07/31/2024.

Prostate-Specific Membrane Antigen PET Response Associates with Metastasis-Free Survival After Stereotactic Ablative Radiation in Oligometastatic Prostate Cancer.

Sutera P, Deek MP, Deek RA, Guler OC, Hurmuz P, Reyhan M, Rowe S, Radwan N, Dipasquale S, Hrinivich WT, Lowe K, Ren L, Saraiya B, Ennis R, Hathout L, Mayer T, Deweese TL, Song DY, Kiess A, Oymak E, Pienta K, Feng F, Pomper M, Ozyigit G, Tran PT, Onal C, Phillips RM

Advances in radiation oncology.. 2024 July 9 (7):101507. Epub 04/13/2024.

Genomic Determinants Associated with Modes of Progression and Patterns of Failure in Metachronous Oligometastatic Castration-sensitive Prostate Cancer.

Sutera P, Song Y, Shetty AC, English K, Van der Eecken K, Guler OC, Wang J, Cao Y, Bazyar S, Verbeke S, Van Dorpe J, Fonteyne V, De Laere B, Mishra M, Rana Z, Molitoris J, Ferris M, Kiess A, Song DY, DeWeese T, Pienta KJ, Barbieri C, Marchionni L, Ren L, Sawant A, Simone N, Berlin A, Onal C, Tran PT, Ost P, Deek MP

European urology oncology.. 2024 June 10 Epub 06/10/2024.

Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTOG 0712.

Rana Z, Kamran SC, Shetty AC, Sutera P, Song Y, Bazyar S, Solanki AA, Simko JP, Pollack A, McConkey D, Kates M, Siddiqui MM, Hiken J, Earls J, Messina D, Mouw KW, Miyamoto D, Shipley WU, Michaelson MD, Zietman A, Coen JJ, Dahl DM, Jani AB, Souhami L, Chang BK, Lee RJ, Pham H, Marshall DT, Shen X, Pugh SL, Feng FY, Efstathiou JA, Tran PT, Deek MP

European urology oncology.. 2024 April 18 Epub 04/18/2024.

Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer.

Deek MP, Sutera P, Jing Y, Gao R, Rothman E, Day H, Chang D, Dirix P, Armstrong AJ, Campbell B, Lopez Campos F, Berenguer M, Ramotar M, Conde-Moreno A, Berlin A, Bosetti DG, Corcoran N, Koontz B, Mercier C, Siva S, Pryor D, Ost P, Huynh MA, Kroeze S, Stish B, Kiess A, Trock B, Tran PT, Gillessen S, Sweeney C

European urology oncology.. 2024 April 2 Epub 04/02/2024.

Identification of a Predictive Genomic Biomarker for Prostate-directed Therapy in Synchronous Low-volume Metastatic Castration-sensitive Prostate Cancer.

Sutera P, Shetty AC, Song Y, Hodges T, Hoang T, Rana Z, Pienta K, Feng F, Song DY, DeWeese T, Gillessen S, Sweeney C, James N, Attard G, Deek M, Tran PT

European urology oncology.. 2024 April 7 (2):241-247. Epub 08/08/2023.

TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment.

Hoang T, Sutera P, Nguyen T, Chang J, Jagtap S, Song Y, Shetty AC, Chowdhury DD, Chan A, Carrieri FA, Hathout L, Ennis R, Jabbour SK, Parikh R, Molitoris J, Song DY, DeWeese T, Marchionni L, Ren L, Sawant A, Simone N, Lafargue A, Van Der Eecken K, Bunz F, Ost P, Tran PT, Deek MP

The Prostate.. 2024 January 84 (1):87-99. Epub 10/09/2023.

Clinical and Genomic Differences Between Advanced Molecular Imaging-detected and Conventional Imaging-detected Metachronous Oligometastatic Castration-sensitive Prostate Cancer.

Sutera P, Song Y, Van der Eecken K, Shetty AC, English K, Hodges T, Chang J, Fonteyne V, Rana Z, Ren L, Mendes AA, Lumen N, Delrue L, Verbeke S, De Man K, Song DY, Pienta K, Feng FY, Joniau S, Lotan T, Lane B, Kiess A, Rowe S, Pomper M, DeWeese T, Deek M, Sweeney C, Ost P, Tran PT

European urology.. 2023 December 84 (6):531-535. Epub 05/10/2023.

Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer.

Sutera PA, Shetty AC, Hakansson A, Van der Eecken K, Song Y, Liu Y, Chang J, Fonteyne V, Mendes AA, Lumen N, Delrue L, Verbeke S, De Man K, Rana Z, Hodges T, Hamid A, Roberts N, Song DY, Pienta K, Ross AE, Feng F, Joniau S, Spratt D, Gillessen S, Attard G, James ND, Lotan T, Davicioni E, Sweeney C, Tran PT, Deek MP, Ost P

Annals of oncology : official journal of the European Society for Medical Oncology. 2023 July 34 (7):605-614. Epub 05/08/2023.

WNT Pathway Mutations in Metachronous Oligometastatic Castration-Sensitive Prostate Cancer.

Sutera P, Deek MP, Van der Eecken K, Shetty AC, Chang JH, Hodges T, Song Y, Verbeke S, Van Dorpe J, Fonteyne V, De Laere B, Mishra M, Rana Z, Molitoris J, Ferris M, Ross A, Schaeffer E, Roberts N, Song DY, DeWeese T, Pienta KJ, Antonarakis ES, Ost P, Tran PT

International journal of radiation oncology, biology, physics.. 2023 April 1115 (5):1095-1101. Epub 01/26/2023.

Long-Term Outcomes and Genetic Predictors of Response to Metastasis-Directed Therapy Versus Observation in Oligometastatic Prostate Cancer: Analysis of STOMP and ORIOLE Trials.

Deek MP, Van der Eecken K, Sutera P, Deek RA, Fonteyne V, Mendes AA, Decaestecker K, Kiess AP, Lumen N, Phillips R, De Bruycker A, Mishra M, Rana Z, Molitoris J, Lambert B, Delrue L, Wang H, Lowe K, Verbeke S, Van Dorpe J, Bultijnck R, Villeirs G, De Man K, Ameye F, Song DY, DeWeese T, Paller CJ, Feng FY, Wyatt A, Pienta KJ, Diehn M, Bentzen SM, Joniau S, Vanhaverbeke F, De Meerleer G, Antonarakis ES, Lotan TL, Berlin A, Siva S, Ost P, Tran PT

Journal of clinical oncology : official journal of the American Society of Clinical Oncology.. 2022 October 1040 (29):3377-3382. Epub 08/24/2022.

Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics.

Sutera P, Van Der Eecken K, Kishan AU, Hamid A, Grist E, Attard G, Lotan T, Mendes AA, Paller CJ, Carducci MA, Ross A, Wang H, Pienta K, Feng FY, Antonarakis ES, Ost P, Song DY, Greco S, Deville C, DeWeese T, Tran PT, Deek MP

Prostate cancer and prostatic diseases.. 2022 April 25 (4):713-719. Epub 01/11/2022.

Post-Operative Morbidity and Mortality Following Total Neoadjuvant Therapy Versus Conventional Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer.

Sutera P, Solomina J, Wegner RE, Abel S, Monga D, Finley G, McCormick J, Kirichenko AV

Journal of gastrointestinal cancer.. 2021 September 52 (3):976-982. Epub 1900 01 01.

Early Exploratory Analysis for Patient-reported Quality of Life and Dosimetric Correlates in Hypofractionated Stereotactic Body Radiation Therapy (SBRT) for Low-risk and Intermediate-risk Prostate Cancer: Interim Results from a Prospective Phase II Clinical Trial.

Iarrobino NA, Gill B, Sutera PA, Kalash R, D' Ambrosio D, Heron DE

American journal of clinical oncology.. 2019 November 42 (11):856-861. Epub 1900 01 01.

Is Multifocal Regression a Risk Factor for Ipsilateral Breast Tumor Recurrence in the Modern Era After Neoadjuvant Chemotherapy and Breast Conservation Therapy?

Ling DC, Sutera PA, Iarrobino NA, Diego EJ, Soran A, Johnson RR, Bhargava R, Champ CE, Beriwal S

International journal of radiation oncology, biology, physics.. 2019 July 15104 (4):869-876. Epub 03/15/2019.

Initial Results of a Multicenter Phase 2 Trial of Stereotactic Ablative Radiation Therapy for Oligometastatic Cancer.

Sutera P, Clump DA, Kalash R, D'Ambrosio D, Mihai A, Wang H, Petro DP, Burton SA, Heron DE

International journal of radiation oncology, biology, physics.. 2019 January 1103 (1):116-122. Epub 08/25/2018.

Clinical and Molecular Recursive Partitioning Analysis of High-grade Glioma Treated With IMRT.

Sutera P, Kalash R, Flickinger J, Engh J, Heron DE

American journal of clinical oncology.. 2019 January 42 (1):27-35. Epub 1900 01 01.

Stereotactic Ablative Radiation Therapy for Unresectable Colorectal Oligometastases.

Sutera P, Kalash R, Clump DA, D'Ambrosio D, Mihai A, Burton SA, Heron DE

Advances in radiation oncology.. 2019 4 (1):57-62. Epub 09/14/2018.

Initial Results of a Prospective Study of Adjuvant Pancreatic Stereotactic Body Radiation Therapy for Close or Positive Margins.

Bernard ME, Sutera PA, Iarrobino NA, Quan K, Burton SA, Bahary N, Hogg M, Zureikat A, Heron DE

Advances in radiation oncology.. 2019 4 (2):294-301. Epub 11/29/2018.

Mitochondrial dysfunction RAD51, and Ku80 proteolysis promote apoptotic effects of Dinaciclib in Bcl-xL silenced cells.

Premkumar DR, Jane EP, Thambireddy S, Sutera PA, Cavaleri JM, Pollack IF

Molecular carcinogenesis.. 2018 April 57 (4):469-482. Epub 12/30/2017.

Results of a prospective phase 2 clinical trial of induction gemcitabine/capecitabine followed by stereotactic ablative radiation therapy in borderline resectable or locally advanced pancreatic adenocarcinoma.

Quan K, Sutera P, Xu K, Bernard ME, Burton SA, Wegner RE, Zeh H, Bahary N, Stoller R, Heron DE

Practical radiation oncology.. 2018 8 (2):95-106. Epub 10/07/2017.

Stereotactic Body Radiation Therapy for Locally Progressive and Recurrent Pancreatic Cancer after Prior Radiation.

Sutera P, Bernard ME, Wang H, Bahary N, Burton S, Zeh H, Heron DE

Frontiers in oncology.. 2018 8 :52. Epub 03/07/2018.

Prognostic Factors for Elderly Patients Treated With Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma.

Sutera PA, Bernard ME, Wang H, Heron DE

Frontiers in oncology.. 2018 8 :282. Epub 07/27/2018.

Salvage stereotactic radiosurgery for recurrent gliomas with prior radiation therapy.

Sutera PA, Bernard ME, Gill BS, Quan K, Engh JA, Burton SA, Heron DE

Future oncology.. 2017 December 13 (29):2681-2690. Epub 12/04/2017.

Survivin inhibitor YM155 induces mitochondrial dysfunction, autophagy, DNA damage and apoptosis in Bcl-xL silenced glioma cell lines.

Jane EP, Premkumar DR, Sutera PA, Cavaleri JM, Pollack IF

Molecular carcinogenesis.. 2017 April 56 (4):1251-1265. Epub 11/22/2016.

One- vs. Three-Fraction Pancreatic Stereotactic Body Radiation Therapy for Pancreatic Carcinoma: Single Institution Retrospective Review.

Sutera PA, Bernard ME, Gill BS, Harper KK, Quan K, Bahary N, Burton SA, Zeh H, Heron DE

Frontiers in oncology.. 2017 7 :272. Epub 11/14/2017.

Dinaciclib, a Cyclin-Dependent Kinase Inhibitor Promotes Proteasomal Degradation of Mcl-1 and Enhances ABT-737-Mediated Cell Death in Malignant Human Glioma Cell Lines.

Jane EP, Premkumar DR, Cavaleri JM, Sutera PA, Rajasekar T, Pollack IF

The Journal of pharmacology and experimental therapeutics.. 2016 February 356 (2):354-65. Epub 11/19/2015.

Enzymatic C(sp)-H Amination: P450-Catalyzed Conversion of Carbonazidates into Oxazolidinones.

Singh R, Kolev JN, Sutera PA, Fasan R

ACS catalysis.. 2015 March 65 (3):1685-1691. Epub 01/29/2015.

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.